Residual and Late Onset Symptoms Appeared in a Patient with Severe Fever with Thrombocytopenia in a Convalescence Stage

Kanda, Kohei; Iwamoto, Noriko; Kutsuna, Satoshi; Nakamura, Keiji; Okuhama, Ayako; Shimomura, Akira; Inagaki, Takeshi; Yoshikawa, Tomoki; Kurosu, Takeshi; Shimojima, Masayuki; Saijo, Masayuki; Ohmagari, Norio

doi:10.3390/v13040657

Cited by 3 publications

(3 citation statements)

References 19 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A survey by the Ministry of the Environment reported that the habitat area of Japanese deer and wild boars was mainly West Japan, although the area had been spreading northward every year [ 17 , 18 , 19 , 20 ]. A previous study concluded that wildlife habitat area changes also accelerated the spread of infection of Japanese spotted fever and scrub typhus, both of which are related to ticks [ 21 , 22 , 23 ]. The spread of the habitat area of the wild animals may also be associated with the distribution of the ticks carrying the SFTS virus and the differences between regions in terms of case prevalence; therefore, the spread of infection should be studied in the future.…”

Section: Discussionmentioning

confidence: 99%

Clinical Presentation and Mortality of Severe Fever with Thrombocytopenia Syndrome in Japan: A Systematic Review of Case Reports

Yokomizo

Tomozane

Sano

et al. 2022

IJERPH

View full text Add to dashboard Cite

Severe fever with thrombocytopenia syndrome (SFTS) is an infection mediated by ticks and has been reported to have a high mortality rate in Japan. At our hospital, we reported three cases of SFTS with relatively positive outcomes. We reviewed reports of SFTS cases in Japan to clarify the current state of the disease in Japan, the treatment provided, and its outcome. The Ichushi Web was searched for literature using the following terms as keywords: “SFTS” or “severe fever with thrombocytopenia syndrome”. Overall, 174 cases were collected and reviewed. The mean age of patients was 70.69 years old, and the mortality rate was 35%. The dead group was significantly older (p < 0.001) than the alive group, had a significantly shorter period from symptom onset to hospital admission, and experienced significantly more hemorrhage-related and neurological symptoms. Further, the most frequently provided treatment methods were adrenocorticosteroids, antibiotics, and conservative treatment. The low recognition rate of SFTS in Japan might lead to a misdiagnosis or delay in diagnosis and treatment, especially in mild to moderate cases. Medical professionals and citizens who live in areas inhabited by ticks need to be informed about SFTS to appropriately diagnose and manage SFTS cases in Japan in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Presentation and Mortality of Severe Fever with Thrombocytopenia Syndrome in Japan: A Systematic Review of Case Reports

Yokomizo

Tomozane

Sano

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Currently, our knowledge of the convalescent symptoms in patients with SFTS remains limited. Hematospermia, fatigue, myalgia, alopecia, insomnia, and depression were reported during the recovery period of patients with SFTS in a case study in Japan [ 26 ]. Whether these symptoms are 1) a long-term complication occurring after critical care; 2) viral hemorrhagic fever-specific post-acute sequelae, as seen with post-Ebola syndrome; or 3) a post-infection condition that can also be observed in other viral infections, such as severe acute respiratory syndrome coronavirus 2 infection, remains unclear [ 27 – 29 ].…”

Section: Discussionmentioning

confidence: 99%

One-year mortality and morbidities of severe fever with thrombocytopenia syndrome compared with other diseases: A nationwide cohort study in South Korea

Heo,

Park

et al. 2024

PLoS Negl Trop Dis

View full text Add to dashboard Cite

Background The long-term mortality and morbidity of patients with severe fever with thrombocytopenia syndrome (SFTS) remain unclear. Methods This retrospective cohort study was conducted using the National Health Insurance Service dataset on hospitalized patients with SFTS aged ≥20 years between 2016 and 2021 (n = 1,217). Each SFTS case was matched with three controls hospitalized for non-SFTS-related diseases using propensity score matching. The all-cause mortality of patients with SFTS was evaluated during the one-year follow-up and compared with that of controls. Post-discharge events were investigated to determine the effects of SFTS on post-acute sequelae. Results Finally, 1,105 patients with SFTS and 3,315 controls were included. Patients with SFTS had a higher risk of death during the one-year follow-up than that of controls (hazard ratio [HR], 2·26; 95% confidence interval [CI], 1·82–2·81). Thirty-day mortality was significantly higher in the SFTS group (HR, 3·99; 95% CI, 3·07–5·19) than in the control group. An increased risk of death after 31–365 days was observed among controls, though this difference was significant only among patients in their 80s (HR, 0·18; 95% CI, 0·06–0·57). For post-discharge events, patients in the SFTS group exhibited a higher risk of readmission (HR, 1·17; 95% CI, 1·04–1·32) and emergency room visit (HR, 2·32; 95% CI, 1·96–2·76) than those in the control group. Conclusion SFTS induces a higher risk of short-term mortality and post-acute sequelae in hospitalized patients during a one-year follow-up than non-SFTS-related diseases. Our results provide guidance for the management of SFTS.

show abstract

“…In addition, a case of a patient who showed long-term fatigue and myalgia in the recovery phase was reported (32). The patient described in the report also showed hematospermia, alopecia, insomnia, and a depressive mood in the late stage of the recovery phase.…”

Section: Clinical Manifestations and Pathophysiologymentioning

confidence: 96%

Severe Fever with Thrombocytopenia Syndrome, a Viral Hemorrhagic Fever, Endemic to Japan: Achievements in and Directions for Medical Research

Saijo

2022

Jpn J Infect Dis

View full text Add to dashboard Cite

Severe fever with thrombocytopenia syndrome (SFTS), a novel infectious disease caused by a novel bunyavirus and with a high case fatality rate (CFR), was reported by Chinese scientists in 2011. The causative virus, Dabie bandavirus also known as the SFTS virus (SFTSV), belongs to the genus Bandavirus (formerly named Phlebovirus) of the family Phenuiviridae (formerly named Bunyaviridae). SFTS was also reported to be endemic in South Korea and Japan in 2013. SFTSV circulates between some species of ticks and animals in nature. Humans are infected with SFTSV through bites from ticks such as Haemaphysalis longicornis and Amblyomma testidinarium. Domesticated animals, such as cats and dogs, are also infected with SFTSV and shown SFTS-like symptoms with a high CFR, likely having been infected through tick bites in the living environment. Furthermore, there have been cases of patients with SFTS who were infected with SFTSV through close contact with sick cats or dogs. The CFR in patients with SFTS is approximately 30% in Japan. There is always a risk of SFTSV infection in human populations living in endemic areas. Therefore, the development of specific therapies and vaccines is urgently needed to reduce the number of fatal SFTS cases.

show abstract

Residual and Late Onset Symptoms Appeared in a Patient with Severe Fever with Thrombocytopenia in a Convalescence Stage

Cited by 3 publications

References 19 publications

Clinical Presentation and Mortality of Severe Fever with Thrombocytopenia Syndrome in Japan: A Systematic Review of Case Reports

Clinical Presentation and Mortality of Severe Fever with Thrombocytopenia Syndrome in Japan: A Systematic Review of Case Reports

One-year mortality and morbidities of severe fever with thrombocytopenia syndrome compared with other diseases: A nationwide cohort study in South Korea

Severe Fever with Thrombocytopenia Syndrome, a Viral Hemorrhagic Fever, Endemic to Japan: Achievements in and Directions for Medical Research

Contact Info

Product

Resources

About